Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P4H | ISIN: SE0023261292 | Ticker-Symbol: 5JD0
Frankfurt
10.10.25 | 08:18
1,622 Euro
-3,11 % -0,052
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EXPRES2ION BIOTECH HOLDING AB Chart 1 Jahr
5-Tage-Chart
EXPRES2ION BIOTECH HOLDING AB 5-Tage-Chart

Aktuelle News zur EXPRES2ION BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiEXPRES2ION BIOTECH HOLDING AB: VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase1
EXPRES2ION BIOTECH Aktie jetzt für 0€ handeln
MoEXPRES2ION BIOTECH HOLDING AB: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors2
15.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Obtains Top Guarantee Commitments and Subscription Commitments for Warrant Program TO 11, Reflecting Continued Support and Reinforcing Funding2
12.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Announces TO 11 Warrant Exercise Price and Start of Exercise Period19
12.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion to Present in Upcoming Investor Events2
04.09.ExpreS2ion Biotech Holding AB: ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial126Hørsholm, Denmark, 4 September 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine...
► Artikel lesen
02.09.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events2
27.08.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 755
21.08.ExpreS2ion Biotech Holding AB: ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 30397Hørsholm, Denmark, 21 August 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion" or the "Company") is pleased to announce that Pareto Securities has published...
► Artikel lesen
21.08.ExpreS2ion Biotech Holding AB: ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025451Hørsholm, Denmark, 21 August 2025 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its half-year and second quarter 2025 results. The report is available as an attachment and on ExpreS2ion's...
► Artikel lesen
18.07.ExpreS2ion Biotech Holding AB: ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac321Hørsholm, Denmark, 18 July 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, "ExpreS2ion" or the "Company"), a clinical-stage biotechnology company with a focused portfolio...
► Artikel lesen
07.07.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer1
30.06.ExpreS2ion Biotech Holding AB: Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy159Hørsholm, Denmark, 30 June 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2, "ExpreS2ion" or the "Company"), a clinical-stage biotechnology company with a focused portfolio...
► Artikel lesen
24.06.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Announces Pareto Securities Analyst Note on First Patient Dosed in Phase I Trial1
23.06.ExpreS2ion Biotech Holding AB: ExpreS2ion announces dosing of first patient in Phase I clinical trial of ES2B-C001, its novel therapeutic breast cancer immunotherapy148Hørsholm, Denmark, 23 June 2025 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company"), a clinical-stage biotechnology company with a focused portfolio of immunotherapy candidates targeting...
► Artikel lesen
19.06.ExpreS2ion Biotech Holding AB: ExpreS2ion's associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccine215Hørsholm, Denmark, 19 June 2025 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") today announced that its associated company AdaptVac ApS ("AdaptVac"), of which...
► Artikel lesen
28.05.ExpreS2ion Biotech Holding AB: Bulletin from the Annual General Meeting of Expres2ion Biotech Holding AB held on 28 May 2025362The Annual General Meeting 2025 (the "AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 28 May 2025. Notice of the AGM and complete proposals for resolutions taken...
► Artikel lesen
23.05.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report2
21.05.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress1
15.05.EXPRES2ION BIOTECH HOLDING AB: ExpreS2ion announces financial results for the first quarter of 20252
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1